A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial. If approved, the drug, called MariTide, could make Amgen the first new entrant into a market that’s been dominated by Novo Nordisk, which makes Ozempic and Wegovy, and Eli Lilly, which makes Mounjaro and Zepbound.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
